In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating ...

The program targets clear cell Renal Cell Carcinoma (ccRCC), a cancer with significant unmet ... IB-T101 has the potential to transform the treatment landscape for solid tumors, and we are eager to ...

Corvus Pharmaceuticals develops next-gen ITK inhibitors, with promising Phase 1 results. Read why CRVS stock can thrive in ...

Inceptor Bio, a leading innovator in cell therapy, and GRIT Bio, a clinical-stage immunotherapy developer, today announced a strategic partnership to advance IB-T101, a potentially best-in-class CAR-T ...

"National's campaigned on 13 more cancer treatments when we reached Government ... Pharmac also announced that Opdivo, which treats kidney cancer, will be funded from our investment from 1 November.

Manufacturing practices are evolving to advance antibody drug conjugates (ADCs) for cancer treatment through a targeted approach.

Geraldine MacGibbon, Pharmac’s Director Pharmaceuticals said that about 150 people with cancer and 30 people with antibiotic resistant infections could have access to these new medicines from 1 April ...

Various forms of blood cancer exist—all of which are grouped together under the term leukemia. One common form of leukemia is ...

Head and neck squamous cell carcinoma (HNSCC), the seventh most prevalent cancer globally, originates from the mucosal epithelium of the oral cavity, pharynx, and larynx. Traditional risk factors like ...